{"id":53551,"date":"2023-02-01T22:02:15","date_gmt":"2023-02-01T21:02:15","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/hologic-announces-financial-results-for-first-quarter-of-fiscal-2023\/"},"modified":"2023-02-01T22:02:15","modified_gmt":"2023-02-01T21:02:15","slug":"hologic-announces-financial-results-for-first-quarter-of-fiscal-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/hologic-announces-financial-results-for-first-quarter-of-fiscal-2023\/","title":{"rendered":"Hologic Announces Financial Results for First Quarter of Fiscal 2023"},"content":{"rendered":"
\n

\n\u2013 Revenue of $1,074 Million, GAAP Diluted EPS of $0.75, and Non-GAAP Diluted EPS of $1.07 All Exceed Guidance \u2013\n<\/p>\n

\n\u2013 Broad-Based Organic Revenue Growth ex. COVID-19; Diagnostics and Surgical Grow Double-Digits in Constant Currency \u2013\n<\/p>\n

\n\u2013 Company Increases Full-Year Revenue and EPS Guidance \u2013\n<\/p>\n

MARLBOROUGH, Mass.–(BUSINESS WIRE)–$HOLX<\/a> #earnings<\/a>–Hologic, Inc. (Nasdaq: HOLX) announced today the Company\u2019s financial results for the fiscal first quarter ended December 31, 2022.<\/i>\n<\/p>\n

<\/a><\/p>\n

\n\u201cIn our first quarter of fiscal 2023, each of our base franchises exceeded revenue expectations, while also delivering robust profitability,\u201d said Steve MacMillan, the Company\u2019s chairman, president and chief executive officer. \u201cWe had a strong start to our fiscal year with double-digit organic revenue growth ex. COVID-19 in our Diagnostics and Surgical businesses, as well as encouraging signs of recovery in our Breast Health business. In addition, we are increasing our full-year fiscal 2023 guidance for both revenue and EPS, highlighting the confidence we have in our businesses despite an uncertain macro environment.\u201d\n<\/p>\n

\nRecent Highlights<\/span><\/b>\n<\/p>\n